slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 217,291-217,320
Pages 10,126
Rows per page 30
Component
217,291-217,320 of 303,780
18
Crocs | Results Presentation Deck | 40 slidesCrocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations Beat · Action1 hit
19
Includes both GAAP and non-GAAP (Adjusted) metrics.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations Beat · Action1 hit
20
The slide uses donut charts to visualize revenue composition across four key dimensions.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations Beat · Action1 hit
26
Includes footnotes defining Gross Leverage and Net Debt / Adj. EBITDA calculations.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations Beat · Action1 hit
30
Crocs | Results Presentation Deck | 40 slidesCrocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations Beat · Action1 hit
31
Crocs | Results Presentation Deck | 40 slidesCrocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations 1 hit
33
Includes specific footnotes explaining adjustments for distribution centers, HEYDUDE inventory fair value step-up, and inventory reserves in Russia.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations 1 hit
35
Includes footnotes explaining specific adjustments like HEYDUDE integration and Russia operations shutdown.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations 1 hit
36
Includes footnotes (1) and (2) explaining the adjustments.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations 1 hit
37
Includes footnotes regarding non-GAAP income adjustments and intra-entity IP transfers.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations 1 hit
39
Includes explanatory footnotes regarding adjustments for growth investments and intellectual property amortization.Crocs | Results Presentation Deck | 40 slides · Crocs
Conference presentation Investor relations 1 hit
01
The slide uses the etymology of the company name 'Daré' to frame their mission.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
02
Dare Bioscience | Investor Presentation Deck | 27 slidesDare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
03
The slide uses a Gantt-style chart to map product development stages from pre-clinical to FDA approval.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
04
Includes professional credentials, leadership roles, and publication counts for both presenters.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
05
The slide uses a high-contrast blue box to highlight the core product value proposition.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
07
Dare Bioscience | Investor Presentation Deck | 27 slidesDare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
The slide uses a comparison framework to contrast existing treatments for other conditions with the lack of treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
09
This slide outlines regulatory requirements for clinical trial design, including placebo run-in periods, patient population definition, PRO instruments, and primary endpoints.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
10
Dare Bioscience | Investor Presentation Deck | 27 slidesDare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
Includes a visual comparison indicating FSAD is not equal to HSDD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
Uses medical diagnostic criteria (DSM) to frame the business opportunity by analogy.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
13
The slide uses a bulleted list structure to categorize the patient experience into physical symptoms, motivations, emotional impact, and psychological concerns.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
14
Includes a highlighted section emphasizing the 10 million women actively seeking treatment.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
15
Dare Bioscience | Investor Presentation Deck | 27 slidesDare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
16
Includes yellow highlighting on key endpoint descriptions.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
17
The slide uses a funnel-like diagram to represent the patient recruitment and study flow.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
18
The table tracks patient flow from the single-blind run-in period through various analysis sets (ITT, SAS, PP).Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
19
Clinical trial safety data summary.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
20
TEAE = Treatment-Emergent Adverse Event. Data shows comparable safety profiles between treatment and placebo.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations 1 hit